Capricor Therapeutics (CAPR) Tops Q2 EPS by 7c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c